phase II clinical study
FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC
This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations.
Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib
The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib.
Genomic Testing Cooperative to ID Patients for Elevation Oncology's Seribantumab Trial
GTC will use its Solid Tumor Profile Plus test to identify solid cancer patients with NRG1 gene fusions for enrollment in Elevation's Phase II CRESTONE trial.
Rain Therapeutics, Tempus Partner to Identify Patients with MDM2-Amplified Tumors for Basket Trial
Tempus will provide centralized DNA and RNA tumor sequencing to help Rain enroll patients in a Phase II trial for its MDM2 inhibitor.
NeoGenomics, Elevation Oncology Partner on NRG1 Fusion Testing for Clinical Trial Enrollment
NeoGenomics will use its gene fusion panels to identify patients with solid tumors and an NRG1 fusion who might qualify for Elevation's Phase II CRESTONE study.
Jan 22, 2020